Protection against late-onset AIDS in macaques prophylactically immunized with a live simian HIV vaccine was dependent on persistence of the vaccine virus

Journal of Immunology

Volumn 173, Issue 6, 2004, Pages 4100-4107

  Mackay, Glenn A ^a,b   Liu, Zhenqian ^a   Singh, Dinesh K ^a,b   Smith, Marilyn S ^b   Mukherjee, Sampa ^a   Sheffer, Darlene ^a   Jia, Fenglan ^a   Adany, Istvan ^a   Sun, Kelvin H ^a   Dhillon, Sukhbir ^a   Zhuge, Wu ^a   Narayan, Opendra ^a,b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; MONOCLONAL ANTIBODY; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LATENT VIRUS INFECTION; MACACA; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; SUPERINFECTION; T LYMPHOCYTE; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS STRAIN;

EID: 4644247605     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.173.6.4100     Document Type: Article

References (38)

1. Walker, B. D., and E. S. Rosenberg. 2000. Containing HIV after infection. Nat. Med. 6:1094.
2. Shafer, R. W., and D. A. Vuitton. 1999. Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1. Biomed. Pharmacother. 53:73.
3. Yazdanpanah, Y., D. Sissoko, M. Egger, Y. Mouton, M. Zwahlen, and G. Chene. 2004. Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials. Br. Med. J. 328:249.
4. Joag, S. V., Z. Q. Liu, E. B. Stephens, M. S. Smith, A. Kumar, Z. Li, C. Wang, D. Sheffer, F. Jia, L. Foresman, et al. 1998. Oral immunization of macaques with attenuated vaccine virus induces protection against vaginally transmitted AIDS. J. Virol. 72:9069.
5. Johnson, R. P., and R. C. Desrosiers. 1998. Protective immunity induced by live attenuated simian immunodeficiency virus. Curr. Opin. Immunol. 10:436.
6. Haga, T., T. Kuwata, M. Ui, T. Igarashi, Y. Miyazaki, and M. Hayami. 1998. A new approach to AIDS research and prevention: the use of gene-mutated HIV-1/SIV chimeric viruses for anti-HIV-1 live-attenuated vaccines. Microbiol. Immunol. 42:245.
7. Johnson, R. P. 2002. Mechanisms of protection against simian immunodeficiency virus infection. Vaccine 20:1985.
8. Wyand, M. S., K. H. Manson, M. Garcia-Moll, D. Montefiori, and R. C. Desrosiers. 1996. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus, J. Virol. 70:3724.
9. Willey, R. L., R. Byrum, M. Piatak, Y. B. Kim, M. W. Cho, J. J. Rossio, Jr., J. J. Bess, Jr., T. Igarashi, Y. Endo, L. O. Arthur, et al. 2003. Control of viremia and prevention of simian-human immunodeficiency virus-induced disease in rhesus macaques immunized with recombinant vaccinia viruses plus inactivated simian immunodeficiency virus and human immunodeficiency virus type 1 particles. J. Virol. 77:1163.
10. Daniel, M. D., F. Kirchhoff, S. C. Czajak, P. K. Sehgal, and R. C. Desrosiers. 1992. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258:1938.
11. Kumar, A., J. D. Lifson, Z. Li, F. Jia, S. Mukherjee, I. Adany, Z. Liu, M. Piatak, D. Sheffer, H. M. McClure, and O. Narayan. 2001. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency virus (SHIV). Virology 279:241.
12. KU inoculated into immunized macaques caused infection, but virus burdens progressively declined with time. J. Virol. 74:10489.
13. Li, J., C. I. Lord, W. Haseltine, N. L. Letvin, and J. Sodroski. 1992. Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J. Acquired Immune Defic. Syndr. 5:639.
14. + T cells and AIDS in pig-tailed macaques. J. Virol. 70:3189.
15. + T cell loss and AIDS in rhesus macaques. J. Med. Primatol. 27:59.
16. KU-1. AIDS Res. Hum. Retroviruses 16:1573.
17. + lymphocytes. Science 283:857.
18. + T-cell-depleted macaques. AIDS 16:829.
19. Joag, S. V., R. J. Adams, D. M. Pinson, I. Adany, and O. Narayan. 1994. Intracerebral infusion of TNF-α and IL-6 failed to activate latent SIV infection in the brains of macaques inoculated with macrophage-tropic neuroadapted SIVmac. J. Leukocyte Biol. 56:353.
20. Mackay, G. A., Y. Niu, Z. Q. Liu, S. Mukherjee, Z. Li, I. Adany, S. Buch, W. Zhuge, H. M. McClure, O. Narayan, and M. S. Smith. 2002. Presence of Intact vpu and nefgenes in nonpathogenic SHIV is essential for acquisition of pathogenicity of this virus by serial passage in macaques. Virology 295:133.
21. Hofmann-Lehmann, R., R. K. Swenerton, V. Liska, C. M. Leutenegger, H. Lutz, H. M. McClure, and R. M. Ruprecht. 2000. Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load: comparison of one- versus two-enzyme systems. AIDS Res. Hum. Retroviruses 16:1247.
22. Kitrinos, K. M., N. G. Hoffman, J. A. Nelson, and R. Swanstrom. 2003. Turnover of env variable region 1 and 2 genotypes in subjects with late-stage human immunodeficiency virus type 1 infection. J. Virol. 77:6811.
23. Thompson, J. D., D. G. Higgins, and T. J. Gibson. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22:4673.
24. Jensen, L. J., R. Gupta, N. Blom, D. Devos, J. Tamames, C. Kesmir, H. Nielsen, H. H. Staerfeldt, K. Rapacki, C. Workman, et al. 2002. Prediction of human protein function from post-translational modifications and localization features. J. Mol. Biol. 319:1257.
25. Hansen, J. E., O. Lund, N. Tolstrup, A. A. Gooley, K. L. Williams, and S. Brunak. 1998. NetOglyc: prediction of mucin type O-glycosylation sites based on sequence context and surface accessibility. Glycoconj. J. 15:115.
26. Blom, N., S. Gammeltoft, and S. Brunak. 1999. Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. J. Mol. Biol. 294:1351.
27. Kreegipuu, A., N. Blom, and S. Brunak. 1999. PhosphoBase, a database of phosphorylation sites: release 2.0. Nucleic Acids Res. 27:237.
28. Joag, S. V., M. G. Anderson, J. E. Clements, M. F. McEntee, D. P. Sharma, R. J. Adams, and O. Narayan. 1993. Antigenic variation of molecularly cloned SIVmac239 during persistent infection in a rhesus macaque. Virology 195:406.
29. Vogel, T. U., T. C. Friedrich, D. H. O'Connor, W. Rehrauer, E. J. Dodds, H. Hickman, W. Hildebrand, J. Sidney, A. Sette, A. Hughes, et al. 2002. Escape in one of two cytotoxic T-lymphocyte epitopes bound by a high-frequency major histocompatibility complex class I molecule, Mamu-A*02: a paradigm for virus evolution and persistence? J. Virol. 76:11623.
30. Allen, T. M., D. H. O'Connor, P. Jing, J. L. Dzuris, B. R. Mothe, T. U. Vogel, E. Dunphy, M. E. Liebl, C. Emerson, N. Wilson, et al. 2000. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 407:386.
31. O'Connor, D. H., T. M. Allen, T. U. Vogel, P. Jing, I. P. DeSouza, E. Dodds, E. J. Dunphy, C. Melsaether, B. Mothe, H. Yamamoto, et al. 2002. Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat. Med. 8:493.
32. Cheng-Mayer, C., A. Brown, J. Harouse, P. A. Luciw, and A. J. Mayer. 1999. Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation. J. Virol. 73:5294.
33. Yokomaku, Y., H. Miura, H. Tomiyama, A. Kawana-Tachikawa, M. Takiguchi, A. Kojima, Y. Nagai, A. Iwamoto, Z. Matsuda, and K. Ariyoshi. 2004. Impaired processing and presentation of cytotoxic-T-lymphocyte (CTL) epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type 1 infection. J. Virol. 78:1324.
34. Geels, M. J., M. Comelissen, H. Schuitemaker, K. Anderson, D. Kwa, J. Maas, J. T. Dekker, E. Baan, F. Zorgdrager, B. R. van den, et al. 2003. Identification of sequential viral escape mutants associated with altered T-cell responses in a human immunodeficiency virus type 1-infected individual. J. Virol. 77:12430.
35. + T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189:991.
36. Barouch, D. H., J. Kunstman, M. J. Kuroda, J. E. Schmitz, S. Santra, F. W. Peyerl, G. R. Krivulka, K. Beaudry, M. A. Lifton, D. A. Gorgone, et al. 2002. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415:335.
37. Barouch, D. H., and N. L. Letvin. 2002. Viral evolution and challenges in the development of HIV vaccines. Vaccine 20(Suppl. 4):A66.
38. Chen, Z. W., A. Craiu, L. Shen, M. J. Kuroda, U. C. Iroku, D. I. Watkins, G. Voss, and N. L. Letvin. 2000. Simian immunodeficiency virus evades a dominant epitope-specific cytotoxic T lymphocyte response through a mutation resulting in the accelerated dissociation of viral peptide and MHC class I. J. Immunol. 164:6474.